Ipilimumab
| Ipilimumab?
| |
| Therapeutic monoclonal antibody | |
| Source | Human |
| Target | CTLA-4 |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C6742H9972N1732O2004S40 |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Ipilimumab | |
|
Articles | |
|---|---|
|
Most recent articles on Ipilimumab | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Ipilimumab at Clinical Trials.gov Clinical Trials on Ipilimumab at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Ipilimumab
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Ipilimumab Discussion groups on Ipilimumab Patient Handouts on Ipilimumab Directions to Hospitals Treating Ipilimumab Risk calculators and risk factors for Ipilimumab
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Ipilimumab | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Overview
Ipilimumab (also known as MDX-010) is a human monoclonal antibody being developed by Bristol-Myers Squibb and Medarex. It is intended to be used as a drug to activate the immune system. Ipilimumab is undergoing clinical trials for the treatment of melanoma.[1]
Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that is believed to play a critical role in regulating natural immune responses. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.
As of October 2007 there are two fully human anti CTLA-4 [1] monoclonal antibodies in advanced clinical trials. Ipilimumab, which is an IgG1 isotype, and Tremelimumab (from Pfizer) which is an IgG2 isotype.
References
Human monoclonal antibodies ("-u-") | |
|---|---|
| "-limu-" (immune system) | immunosuppression: Adalimumab, Atorolimumab, Gantenerumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab, Ziralimumab
immune activation: Ipilimumab, Tremelimumab other: Bertilimumab |
| "-kinu-" (interleukin as target) | Canakinumab |
| "-tumu-" (cancer immunotherapy) | Adecatumumab, Anetumumab, Belimumab, Duntumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Votumumab, Zalutumumab, Zanolimumab |
| "-osu-" (bone) | Denosumab |
| "-mulu-" (musculoskeletal) | Durimulumab, Durmulumab, Stamulumab |
| "-fungu-" (fungal) | Efungumab |
| "-viru-" (viral) | Exbivirumab, Libivirumab, Regavirumab, Sevirumab, Tuvirumab |
| "-bacu-" (bacterial) | Nebacumab, Raxibacumab |
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
